top of page

IPC Issues Safety Alert for Nimesulide: Warns of Skin Rash Risk

The Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert for Nimesulide, an anti-inflammatory medication commonly used to treat inflammatory conditions, fever, and pain. The alert warns of the potential for Nimesulide to cause skin rashes, specifically a condition known as "fixed drug eruption."

Nimesulide belongs to the class of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and works by reducing pain, inflammation, and swelling in the body. While adverse effects are rare, they can include skin rash, nausea, vomiting, diarrhea, and elevated liver enzymes.

The IPC is urging healthcare professionals and consumers to closely monitor for any adverse reactions to Nimesulide and to report them to the National Coordination Centre-Pharmacovigilance Programme of India. It is essential to use Nimesulide under the guidance of a healthcare professional, especially for individuals with existing health conditions or allergies.

Nimesulide should not be used by individuals with certain conditions, including blood coagulation issues, stomach ulcers, heart failure, or liver and kidney conditions. It is also not recommended for use in children.

If a reaction occurs while taking Nimesulide, it is advised to consult a doctor immediately. Despite being banned in some countries, Nimesulide is still used for adults in India, but caution is advised.



bottom of page